

Appendix 1: Disclosure in accordance with the Swiss Medtech Transparency Guidelines dated January 1, 2018

Reporting Year 2025

Name of the medical institution	Business address	Training grant to support educational events organized by third parties (annual amount)	Subject/Purpose (optional)	Other educational grants to medical institutions (i.e., scholarships, fellowship programs, and/or grants for public awareness campaigns)	Subject/Purpose (optional)
Universitätsklinikum Ulm	Albert-Einstein-Allee 41 89081 Ulm	2,000 EUR (w/o VAT)			
European Association for the Study of Diabetes (EASD)	Rheindorfer Weg 3 40591 Düsseldorf, Germany	20,000 EUR (w/o VAT)			
Kerngruppe Diabetes und Endokrinologie KGDE	c/o Medworld AG Sennweidstrasse 46 6312 Steinhausen	12,000 CHF (w/o VAT)			
Centre hospitalier universitaire vaudois (CHUV)	Rue du Bugnon 21 1011 Lausanne	700 CHF (w/o VAT)			
Hôpitaux Universitaires Genève (HUG)	Rue Gabrielle-Perret-Gentil 4 1211 Genève 14	3,450 CHF (w/o VAT)			
SGED - Schweizerische Gesellschaft für Endokrinologie und Diabetologie	Rütistrasse 3a 5400 Baden	13,200 CHF (w/o VAT)			

Description of the methodology in accordance with Chapter 1, Section 4 of the Transparency Guidelines: In accordance with the Swiss Medtech Code of Ethical Business Conduct and the Swiss Medtech Transparency Guidelines, mylife Diabetes Care AG discloses the educational grants it provides to healthcare organizations (HCOs) or third-party organizers of educational events for healthcare professionals. This report covers the transitional period from 1 July 2025 to 30 June 2026. Grants relating to January-June 2025 were disclosed by Ypsomed AG, the former owner of the diabetes care business unit. Educational grants are governed by a written internal policy, subject to Compliance oversight, and documented through a structured review and approval process. Data was reconciled for completeness and aggregated at HCO level. All amounts are disclosed in CHF or EUR, exclusive of VAT. Annex 1 is submitted to Swiss Medtech for publication.

Company Name: mylife Diabetes Care AG

Date: June 30, 2026

Note:
Swiss Medtech is not responsible for the accuracy of the disclosed data. The disclosed information will remain publicly available for at least three calendar years after its initial publication.